BREAKING
Home » Posts Tagged "chikungunya vaccine"

FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

By

NewsDesk @bactiman63 Specialty vaccine company, Valneva, announced that the U.S. Food and Drug Administration (FDA) has completed a filing review of its Biologics License Application for Valneva’s single-shot...

Chikungunya vaccine candidate: Antibody levels remained stable from month 6 to month 12

By

By NewsDesk  @bactiman63 Vaccine company, Valneva, announced Monday positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553. Following...

Chikungunya vaccine candidate Phase 3 trial: Induced neutralizing antibody titers in 98.5% of subjects after a single vaccination

By

Specialty vaccine company, Valneva, announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 was recently awarded Breakthrough...

Chikungunya: Valneva awarded Breakthrough Therapy Designation for vaccine candidate

By

By NewsDesk  @infectiousdiseasenews Specialty vaccine company, Valneva announced recently it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553,...

Chikungunya Vaccine Candidate: Valneva completes recruitment for Phase 3 trial

By

Vaccine company, Valneva, announced that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya...

Chikungunya Vaccine Candidate Awarded EMA Prime Designation

By

Specialty vaccine company, Valneva, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation for its single-shot Phase 3 chikungunya vaccine candidate...

Chikungunya vaccine enters Phase 3 clinical trial

By

Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the initiation of a pivotal Phase 3 clinical trial for its differentiated, single-shot...

Chikungunya vaccine: The Lancet provides a detailed analysis of final Phase 1 results

By

Valneva SE, a specialty vaccine company, announced today the publication of full data from the Phase 1 clinical trial of its chikungunya vaccine candidate, VLA1553, in the peer-reviewed medical journal The...

Chikungunya vaccine: Valneva completes End-of-Phase 2 meeting with FDA

By

Valneva SE announced this week that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and agreed on the clinical development plan towards licensure...

Chikungunya vaccine: Valneva reports excellent final Phase 1 results

By

Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced excellent final Phase 1 results for its single-shot chikungunya...